Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

MassMutual Private Wealth & Trust FSB boosted its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 58.2% in the 4th ...

Most people associate sunburns with DNA damage -- it's what we've been taught in textbooks and by dermatologists for years.

Large-cap Health Care company Moderna has logged a 0.6% change today on a trading volume of 6,193,314. The average volume for ...

New research reveals that sunburn may be caused by RNA damage, not DNA, challenging long-held beliefs about UV exposure ...